Clinical Cell Processing News series highlights and reviews new products and techniques for clinical-grade cell processing and manufacturing. Cell processing devices, cultureware, bioreactors, GMP-grade reagents, cell separation techniques… If you would like to promote your product or platform, contact us!
1. Validation of a novel marrow filter device (Kaneka) for mesenchymal stromal cells enrichment (Cytotherapy)
Human bone marrow cells from eight healthy donors were processed using a marrow filter device and, in parallel, using buoyant density centrifugation by two independent investigators.
The marrow filter device generated significantly greater initial cell recovery requiring less investigator time and resulted in approximately 2.5-fold more MSCs after the second passage. The immunophenotype and differentiation potential of MSCs isolated using the two methods were equivalent and consistent with the defining criteria.
2. Short-term stability of human expanded mesenchymal stem cells after harvest (Cytotherapy)
We examined the viability, self-renewal capacity and differentiation capability of MSCs on short-term in vitro storage in saline or dextrose solution at 4°C and room temperature.
Storage of culture-harvested MSCs for >2 h is likely to result in suboptimal MSC-mediated tissue regeneration because of decreased cell viability and differentiation capacity.
3. Impact of storage temperature and processing delays on cord blood quality (Transfusion)
We compared units stored at room temperature (RT) or at 4°C for 72 hours before cryopreservation to units processed shortly after collection (<12 hr). Postthaw results showed similar in vitro characteristics between immediate processing and 4°C storage for cell recovery and viability, both significantly higher than RT storage. Surprisingly, we demonstrated that storage of CB units at RT before processing and cryopreservation profoundly altered in vivo hematopoietic reconstitution in mice, although in vitro hematopoietic colony-forming unit potential was unaltered.
4. Pre-clinical evaluation of CellCap device for harvesting and selecting adipose stem cells (PLoS ONE)
This study utilised primary rat adipose to validate a novel strategy for selecting adult stem cells. Experiments explored the use of large, very dense cell-specific antibody loaded isolation beads (diameter 5x–10x greater than target cells) which overcome the problem of endocytosis and have proved to be very effective in cell isolation from minimally processed primary tissue.
5. Stability of cell populations in cord blood stored 96 hours at room temperature before processing (Transfusion)
CD34+ cells and mature T lymphocytes increased (viability 99%). Mature B lymphocytes and MSCs decreased, maintaining viability. Granulocytes decreased with loss of viability. Monocytes and immature B lymphocytes remained stable. Clonogenic assays showed a decrease in colony-forming unit (CFU) number in UCB units stored for 96 hours.
UCB manipulation did not influence cell viability. All cell subsets remained viable until 96 hours after collection.
6. Pre-clinical evaluation of Tisseel fibrin spray system for delivery of adipose-derived stromal vascular fraction (Cytotherapy)
Our results indicate that mesenchymal and endothelial progenitor cells, prepared in a closed system from unpassaged lipoaspirate samples, retain their growth and differentiation capacity when applied and immobilized on a substrate using a clinically approved fibrin sealant spray system.
7. Development computerized system for clinical cell processing, collection and administration (J Oncol Pract)
… Partners Healthcare System Information Services (PHS-IS; Boston, MA) has worked with oncologists and staff in the cell processing laboratory at the Dana-Farber Cancer Institute (Boston, MA) to develop and implement a novel, comprehensive computerized system for physician ordering and management of cellular products. A multidisciplinary team was formed to accomplish the task of developing a cellular product management system.
In addition, the biotherapy applications were put into use by additional groups of providers when the Dendreon (Seattle, WA) product sipuleucel-T received FDA approval for treatment of patients with prostate cancer.